Showing 2881-2890 of 5831 results for "".
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- Tissue Regeneration Leader Takes Home 2016 Furumoto Award at ASLMS 2016https://practicaldermatology.com/news/tissue-regeneration-leader-takes-home-2016-furumoto-award-at-aslms-2016/2458627/Praveen Arany, DDS, PhD will receive the 2016 ASLMS Dr. Horace Furumoto Innovations Young Investigator Award during the Plenary Session at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS).
- Victoria Kennedy receives ASLMS' First Leadership, Mentorship & Public Advocacy for Women in Medical Science Awardhttps://practicaldermatology.com/news/victoria-kennedy-receives-aslms-first-leadership-mentorship-public-advocacy-for-women-in-medical-science-award/2458628/Victoria Reggie Kennedy will receive the first Leadership, Mentorship & Public Advocacy for Women in Medical Science Award at the annual meeting of the American Society for Laser Medicine and Surgery (ASLMS). The award will be presented at th
- FDA Clears Venus Versa for 20-Plus Common Clinical Indicationshttps://practicaldermatology.com/news/fda-clears-venus-versatm-for-20-plus-common-clinical-indications/2458632/The U.S. Food and Drug Administration cleared Venus Concept’s Venus Versa™ system for skin rejuvenation, hair removal, facial wrinkles and rhytides, skin resurfacing, pigmented and vascular lesions, and acne vulgaris.
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- FDA Proposes Ban on Most Powdered Medical Gloveshttps://practicaldermatology.com/news/fda-proposes-ban-on-most-powdered-medical-gloves/2458639/The FDA has proposed a ban on most powdered gloves in the United States. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care providers, patients and other individuals who are exposed to them, which cannot be corrected t
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- FDA Approves PMA Supplement for MelaFind from STRATA Scienceshttps://practicaldermatology.com/news/fda-accepts-pma-for-melafind-from-strata-sciences/2458644/The FDA has approved STRATA Skin Sciences, Inc.’s PMA supplement for the MelaFind System. The FDA approved MelaFind’s use of the “classifier score data”, a quantitative result derived by the MelaFind System that can be beneficially used in conjunction with the previously a
- Do the FDA's Proposed Regulations on Tanning Bed Use Go Far Enough?https://practicaldermatology.com/news/do-the-fdas-proposed-regulations-on-tanning-bed-use-go-far-enough/2458646/As the comment period on the US Food and Drug Administration’s proposal to restrict tanning bed use winds down, researchers are weighing in on the proposal's merits and potential shortfalls. Investigators